Skip to content
Back to Blog
Bio
2026-04-067 min read53

The AI-Accelerated Drug Discovery Era: Boosting Clinical Efficiency and Leveraging Government Support

In 2026 where AI has become essential for drug discovery, this guide covers AI applications from target identification to clinical optimization and government support strategies for biotech SMEs.

KITIM Consulting Team

AI Becomes Essential in Drug Discovery

In 2026, AI has become not just an option but an essential element in the pharmaceutical and biotech industry. Over 90% of global pharmaceutical companies have integrated AI into their drug development pipelines, and AI-derived drug candidates entering clinical trials are surging.

The Korean government actively supports AI drug development. The MFDS has established new clinical outcome evaluation models incorporating AI and digital healthcare technology and expanded fast-track listing procedures for all innovative drugs.

How AI Transforms Drug Development

Traditional vs. AI-Based Process

| Stage | Traditional | AI-Based | Time Savings |

|-------|-----------|----------|-------------|

| Target Discovery | 3-5 years | 6-12 months | 70% reduction |

| Lead Optimization | 2-3 years | 3-6 months | 80% reduction |

| Preclinical | 1-2 years | 6-12 months | 40% reduction |

| Clinical Design | 6-12 months | 1-3 months | 70% reduction |

| Total Cost | 2-3T KRW | 500B-1T KRW | 50-70% savings |

Core AI Application Areas

1. Target Identification

  • Disease-related target discovery through genomic and proteomic big data analysis
  • Drug Repositioning: Finding new indications for existing drugs
  • Multi-omics data integration analysis
  • 2. Molecular Design

  • Generative AI for automatic optimal molecular structure design
  • ADMET prediction (absorption, distribution, metabolism, excretion, toxicity)
  • Deriving practical candidates considering synthetic feasibility
  • 3. Clinical Trial Optimization

  • Accelerated patient recruitment: Auto-identification through EMR analysis
  • Dose optimization: Simulation-based optimal dosing
  • Biomarker discovery: Response-predictive biomarkers for improved success rates
  • Real-world data (RWD) utilization to reduce clinical trial scale
  • 4. Safety Prediction

  • Clinical adverse event prediction based on preclinical toxicity data
  • Cross-analysis with similar drug databases
  • Long-term safety profile simulation
  • AI Utilization Strategies for Biotech SMEs

    Strategy 1: Partner with AI Platform Companies

    Building in-house AI capabilities is time and cost intensive. Partnering with specialized AI bio platforms is more efficient.

  • Domestic: Standigm, Pharos iBio, Deargen, etc.
  • Global: Insilico Medicine, Recursion, Exscientia, etc.
  • Collaboration model: Milestone-based royalty contracts to minimize upfront costs
  • Strategy 2: Leverage Public AI Infrastructure

  • National Bio Big Data: Free/affordable access to genomic and clinical data
  • AI Hub: Public AI models and datasets for drug development
  • KISTI Supercomputing: Molecular simulation computing resources
  • Strategy 3: AI+CRO Combined Model

  • Leverage CRO AI capabilities
  • Apply AI-based Adaptive Clinical Design
  • 30~50% shorter clinical periods, 20~40% cost reduction
  • Government Support Programs Overview

    R&D Support

    | Program | Content | Scale |

    |---------|---------|-------|

    | Multi-ministry Drug Development | Full preclinical-to-clinical support | Up to billions KRW per project |

    | AI Drug Discovery Platform | AI model and data construction | 1-3B KRW annually |

    | Phase 3 Specialized Fund | Investment linkage | Total 150B KRW |

    | TIPS Bio | Early-stage R&D | Up to 800M KRW |

    Regulatory Support

  • Innovative medical device designation: AI-based diagnostic/therapeutic software
  • Fast-track review: Priority review for AI-leveraged innovative drugs
  • Regulatory sandbox: Regulatory flexibility through demonstration special approval
  • Tax Benefits

  • R&D tax credit: Up to 40% deduction for AI-related R&D costs (SMEs)
  • National strategic technology credit: Additional benefits as AI is designated strategic technology
  • Key Checklist for AI Drug Discovery Success

  • Data quality: AI performance is proportional to data quality
  • IP strategy: Patent filing strategy for AI-generated molecules
  • Regulatory readiness: Confirm regulatory acceptance of AI-based evidence
  • Talent: Recruit bio+AI convergence talent or engage external experts
  • Partnership network: Build collaboration systems with AI companies, CROs, and academia
  • KITIM Bio & AI Consulting

    KITIM provides comprehensive consulting for biotech SMEs leveraging AI in drug development.

  • AI adoption assessment: Recommend AI utilization strategies suited to company pipelines
  • Government R&D matching: Discover and support applications for AI drug development programs
  • Partnership advisory: Design collaboration structures with AI biotechs and CROs
  • AI Drug DiscoveryArtificial IntelligenceClinical TrialsBiotechDigital HealthGovernment Support

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.